Subscribe

What are you looking for?

Main Menu

明報新聞網

和黃醫藥、信達生物治癌新藥上市獲藥監局受理

Future Wealths
Future Wealths
5 6 月, 2025
One Min Read
11 Views
0 Comments
和黃醫藥(0013)公布，和信達生物(1801)聯合宣布呋喹替尼（fruquintinib）和信迪利單抗（sintilimab） 聯合療法用於治療既往接受過一種酪氨酸激酶抑制劑治療失敗的局部晚期或轉移性的腎細胞癌患者的新藥上市申請已獲中國國家藥品監督管理局（「國家藥監局」）受理。

原文: https://finance.mingpao.com/fin/instantf/20250605/1749090449828/%e5%92%8c%e9%bb%83%e9%86%ab%e8%97%a5-%e4%bf%a1%e9%81%94%e7%94%9f%e7%89%a9%e6%b2%bb%e7%99%8c%e6%96%b0%e8%97%a5%e4%b8%8a%e5%b8%82%e7%8d%b2%e8%97%a5%e7%9b%a3%e5%b1%80%e5%8f%97%e7%90%86

Last Update: 5 6 月, 2025

Please share this article if you like it!

Link Copied!
Future Wealths
Written By

Future Wealths

Other Articles

Related Posts

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept